RECENT ADVANCES - THE CYTOCHROME-P450 ENZYMES

被引:220
作者
SLAUGHTER, RL
EDWARDS, DJ
机构
[1] Department of Pharmacy Practice, CPAHP, Wayne State University, Detroit
关键词
D O I
10.1177/106002809502900612
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Successful application of information on cytochrome P450 to prevent drug interactions and improve the therapeutic risk:benefit ratio can occur only if we know which enzyme is responsible for the metabolism of a drug. Until recently, this information was not usually available when new drugs reached the market. It is not enough to know the fraction of a dose metabolized versus excreted unchanged or the metabolic pathways by which a compound is degraded. Studies conducted during drug development must identify the enzyme or enzymes involved in the metabolism of new drugs. In addition, the ability of new drugs to inhibit or induce the activity of the key P450 enzymes must be known if we are to take full advantage of our current knowledge of how the cytochrome P450 system works.
引用
收藏
页码:619 / 624
页数:6
相关论文
共 63 条
  • [1] GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS
    AGUNDEZ, JAG
    MARTINEZ, C
    LEDESMA, MC
    LADONA, MG
    LADERO, JM
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) : 412 - 417
  • [2] IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    TASSANEEYAKUL, W
    TASSANEEYAKUL, W
    MEYER, UA
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) : 521 - 530
  • [3] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN
    BERTILSSON, L
    LOU, YQ
    DU, YL
    LIU, Y
    KUANG, TY
    LIAO, XM
    WANG, KY
    REVIRIEGO, J
    ISELIUS, L
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 388 - 397
  • [4] IN-VITRO APPROACHES CAN PREDICT HUMAN DRUG-METABOLISM
    BIRKETT, DJ
    MACKENZIE, PI
    VERONESE, ME
    MINERS, JO
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (08) : 292 - 294
  • [5] DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES
    BUTLER, MA
    LANG, NP
    YOUNG, JF
    CAPORASO, NE
    VINEIS, P
    HAYES, RB
    TEITEL, CH
    MASSENGILL, JP
    LAWSEN, MF
    KADLUBAR, FF
    [J]. PHARMACOGENETICS, 1992, 2 (03): : 116 - 127
  • [6] CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237
  • [7] CHIBA K, 1993, J PHARMACOL EXP THER, V266, P52
  • [8] GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN
    DAHL, ML
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1993, 3 (02): : 61 - 70
  • [9] ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION
    DAHL, ML
    JOHANSSON, I
    PALMERTZ, MP
    INGELMANSUNDBERG, M
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) : 12 - 17
  • [10] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419